<i>RRAS</i> and <i>RRAS2</i> Mutations Are Recurrent Oncogenic Drivers in Lung Cancer and Are Sensitive to the Pan-RAS Inhibitor RMC-6236
RRASQ87L and RRAS2Q72L are recurrent, oncogenic, and potentially actionable drivers in NSCLC. Our study supports the inclusion of RRAS/RRAS2 into routine molecular diagnostic panels for precision oncology and provides preclinical rationale for investigating the potential therapeutic utility of pan-RAS inhibitors for patients with RRASQ87L/RRAS2Q72L-mutant lung cancers.
Authors
- Jenna-Marie Dix (ORCID: https://orcid.org/0000-0001-8822-4049)
- Tom Zhang (ORCID: https://orcid.org/0009-0007-0979-9719)
- Marc Ladanyi
- Romel Somwar
- Andrea Gazzo (ORCID: https://orcid.org/0009-0009-9282-4667)
- Kathryn C. Arbour (ORCID: https://orcid.org/0000-0001-5951-8427)
- I. Khodos
- Marissa S. Mattar (ORCID: https://orcid.org/0000-0002-2846-9914)
- Alexander J. Pfeil (ORCID: https://orcid.org/0000-0002-5159-019X)
- Leo Gili
- Christopher A. Febres‐Aldana
- S Y Yang
- Rohan P Master
- Juan Luis Gomez Marti
- Ryan Cheng
- Rachel Lai
- Elisa de Stanchina
Institutions
- University of North Carolina at Chapel Hill (US)
- Memorial Sloan Kettering Cancer Center (US)
- New York Medical College (US)
- Lenox Hill Hospital (US)
- National Cancer Institute (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-16
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2734
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00